N-甲基-2-噻吩甲胺盐酸盐 | 7404-67-3

• 物质功能分类: 医药中间体 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-甲基-2-噻吩甲胺盐酸盐
• 英文名称: 2-<(methylamino)methyl>thiophene hydrochloride
• 英文别名: N-methyl-1-(thiophen-2-yl)methanamine hydrochloride；N-methyl(2-thienyl)methanaminium chloride；methyl-[2]thienylmethyl-amine; hydrochloride；hydron;N-methyl-1-thiophen-2-ylmethanamine;chloride
• CAS: 7404-67-3
• 化学式: C₆H₉NS*ClH
• mdl: MFCD03306020
• 分子量: 163.671
• InChiKey: PTOIDTSLBDDEGJ-UHFFFAOYSA-N

物化性质

• 熔点：
  189-190 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.44
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  40.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Methyl-(2-thienylmethyl)amine, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Methyl-(2-thienylmethyl)amine, HCl
CAS number: 7404-67-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H9NS.ClH
Molecular weight: 163.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-甲基-2-噻吩甲胺盐酸盐 在 N-羟基邻苯二甲酰亚胺 、 氧气 、 2,4,6-三甲基吡啶高氯酸盐 、 三乙胺 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 12.0h， 生成 N-acetyl-N-methylthiophene-2-carboxamide
  参考文献：
  名称：

  NHPI-Mediated Electrochemical α-Oxygenation of Amides to Benzimides

  摘要：

  DOI：

  10.1021/acs.joc.2c02700
• 作为产物：
  描述：

  2-((甲基亚氨基)甲基)噻吩 在 sodium tetrahydroborate 、 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 N-甲基-2-噻吩甲胺盐酸盐
  参考文献：
  名称：

  基于苯环生物等排体的多靶点 ChEs-MAO B 抑制剂的结构设计：AChE/BChE 选择性开关和类药物表征

  摘要：

  基于结构的药物设计方法侧重于将苯环杂环生物等排体整合到香豆素衍生物中，香豆素衍生物先前被报道为有效的双重AChE-MAO B抑制剂，目的是改善药物样特征。结构-活性关系强调，MAO B 酶裂比 AChE 对生物电子等排环的耐受性更强。有趣的是，碱性氮上的连接子同源性使得能够选择性地从AChE切换到BChE。在目前的工作中，我们鉴定了基于噻吩的电子等排体和双AChE-MAO B（IC50分别为261和15 nM）和BChE-MAO B（IC50分别为375和20 nM）抑制剂。通过被动扩散（PAMPA-HDM）， 和 都是中等水溶性和膜渗透剂。此外，它们能够抵消 SH-SY5Y 细胞中由 H2O 和 6-OHDA 引起的氧化损伤，并预测在模拟血脑屏障的细胞模型中渗透到中枢神经系统。分子动力学 (MD) 模拟揭示了 AChE 和 BChE 识别过程中的关键差异，这些差异是由 到 的基本链同源性促进的。

  DOI：

  10.1016/j.ejmech.2024.116511

文献信息

• Selective synthesis of mono- and di-methylated amines using methanol and sodium azide as C1 and N1 sources
  作者：Kaushik Chakrabarti、Anju Mishra、Dibyajyoti Panja、Bhaskar Paul、Sabuj Kundu

  DOI：10.1039/c8gc00863a

  日期：——

  A Ru(II) complex mediated synthesis of various N,N-dimethyl and N-monomethyl amines from organic azides using methanol as a methylating agent is reported. This methodology was successfully applied for a one-pot reaction of bromide derivatives and sodium azide in methanol. Notably, by controlling the reaction time several N-monomethylated and N,N-dimethylated amines were synthesized selectively. The

  报道了使用甲醇作为甲基化剂，由有机叠氮化物介导的Ru（II）络合物介导的各种N，N-二甲基和N-单甲基胺的合成。该方法已成功应用于溴化物衍生物和叠氮化钠在甲醇中的一锅法反应。明显地，通过控制反应时间，几个N-单甲基化和N，N选择性合成-二甲基化胺。通过与不同有机叠氮化物的制备规模反应以及抗眩晕药倍他司汀的合成，揭示了该串联过程的实际适用性。进行了一些动力学实验和DFT研究，以了解这种转化的机理。
• AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：Biediger Ronald J.

  公开号：US20130236434A1

  公开（公告）日：2013-09-12

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体的结合的方法包括在体外用整合素激动剂处理表达整合素的细胞，其中整合素选自α4β1、α5β1、α4β7、αvβ3和αLβ2群，然后将处理后的细胞与整合素结合配体接触；具有一般式I的整合素激动剂化合物；使用这种激动剂治疗表达整合素的细胞以增强结合的方法；以及包括将激动剂处理的细胞或激动剂化合物给哺乳动物的治疗方法。
• AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：TEXAS HEART INSTITUTE

  公开号：US20150368234A1

  公开（公告）日：2015-12-24

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法包括在体外用整合素激动剂处理表达整合素的细胞，其中整合素被选择自α4β1、α5β1、α4β7、αvβ3和αLβ2组成的群体中的一种，并将处理后的细胞与整合素结合配体接触；具有一般式I的整合素激动剂化合物；用这样的激动剂处理表达整合素的细胞以增强结合的方法；以及包括向哺乳动物施用经激动剂处理的细胞或激动剂化合物的治疗方法。
• Agonists that enhance binding of integrin-expressing cells to integrin receptors
  申请人：Texas Heart Institute

  公开号：EP2881392A1

  公开（公告）日：2015-06-10

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法，包括在体外用整合素的激动剂处理表达整合素的细胞，其中整合素选自由α4β1、α5β1、α4β7、αvβ3和αLβ2组成的组，并使处理过的细胞与整合素结合配体接触；具有通式Ⅰ的整合素激动剂化合物；用这种激动剂处理整合素表达细胞以增强结合的方法；以及治疗方法，包括给哺乳动物施用激动剂处理过的细胞或激动剂化合物。
• Agonists that enhanced binding of integrin-expressing cells to integrin receptors
  申请人：TEXAS HEART INSTITUTE

  公开号：US10035784B2

  公开（公告）日：2018-07-31

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法，包括在体外用整合素的激动剂处理表达整合素的细胞，其中整合素选自由α4β1、α5β1、α4β7、αvβ3和αLβ2组成的组，并使处理过的细胞与整合素结合配体接触；具有通式Ⅰ的整合素激动剂化合物；用这种激动剂处理整合素表达细胞以增强结合的方法；以及治疗方法，包括给哺乳动物施用激动剂处理过的细胞或激动剂化合物。